Announcements Trials
Browse Landscape

Phase

Phase 2 54Phase 1/2 20Phase 3 16Phase 1 5Phase 4 3Phase 2/3 3Phase NA 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Gynecologic 1

Conditions

Breast Neoplasms 2Ovarian Neoplasms 1

Interventions

Saline Solution 10Docetaxel 10Bevacizumab 9nilotinib 8enzalutamide 8Paclitaxel 8Letrozole 8Fentanyl 8Everolimus 8Cyclophosphamide 8Carboplatin 8Bupivacaine 8Lidocaine 7Sodium Chloride 6Oxycodone 6Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 6Erlotinib Hydrochloride 6Dexamethasone 6Capecitabine 6Trastuzumab 5Tobacco Use Cessation Devices 5Surveys and Questionnaires 5Nivolumab 5Hydromorphone 5Adalimumab 5fludarabine 4Zoledronic Acid 4Tranexamic Acid 4Tacrolimus 4Rocuronium 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × Has results × liposomal doxorubicin × Clear all
NCT00727961 2017-06-08

A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 4 Completed
58 enrolled 10 charts
Gynecologic

Ovarian Neoplasms

NCT00604968 2017-06-07

Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059)

Merck Sharp & Dohme LLC

Phase 4 Terminated
25 enrolled 16 charts
Breast

Breast Neoplasms

NCT00779285 2015-07-14

Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED)

Merck Sharp & Dohme LLC

Phase 4 Terminated
1 enrolled 2 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡